Alto Neuroscience(ANRO) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights – Acquisition of potentially best-in-class dopamine agonist combination product candidates, including ALTO- 207, expands precision psychiatry pipeline; guided by compelling PAX-D study results published in The Lancet Psychiatry – – ALTO-207 adds expected late-stage readout in treatment resistant depression within current cash runway; planned Phase 2b trial, designed to be a potentially pivotal study e ...